Sarepta Therapeutics, Inc. announced preliminary revenue guidance for the third quarter ended September 30, 2021. For the third quarter, the company expects its net product revenues for the quarter to be approximately $166.9 million, compared to net product revenues of $121.4 million for the same period of 2020.